A team of researchers from the Universitat Politècnica de València (UPV) and the French National Centre for Scientific Research (CNRS) has developed the world's most advanced software to study the human cerebellum using high-resolution NMR images. Called DeepCeres, this software will help in the research and diagnosis of diseases such as ALS, schizophrenia, autism and Alzheimer's, among others. The work of the Spanish and French researchers has been published in the prestigious journal NeuroImage.

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest – for the first time in a clinical trial – that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.

Astronauts on NASA’s ninth rotational SpaceX crew mission (Crew-9) splashed down off the Florida coast yesterday evening, ending their months-long science expedition onboard the International Space Station (ISSInternational Space Station). Over the course of the mission, the crew supported a variety of investigations sponsored by the ISS National Laboratory®, including research to improve treatments for neurodegenerative conditions, studies to manufacture more effective therapeutics in space, and student-led experiments to prepare the next generation of explorers. Returning crew members include NASANational Aeronautics and Space Administration astronauts Nick Hague, Suni Williams, and Butch Wilmore, who are part of NASA’s Commercial Crew Program, and Roscosmos cosmonaut Aleksandr Gorbunov.

A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP) in Alzheimer’s disease (AD). CD2AP influences amyloid-beta processing, tau pathology, synaptic integrity, and neuroinflammation. The review outlines its cell type-specific effects in neurons and microglia, suggesting new therapeutic possibilities. Understanding these mechanisms could lead to innovative treatment strategies for AD​.